Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun;7(2):101-112.
doi: 10.1007/s40506-015-0046-4.

Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery

Susanne Doblecki-Lewis  1 , Stephanie Cohen  2 , Albert Liu  3
Affiliations

Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery

Susanne Doblecki-Lewis et al. Curr Treat Options Infect Dis. 2015 Jun.

Abstract

Pre-exposure prophylaxis (PrEP) is an effective and evidence-based HIV-prevention option and is recommended for individuals with substantial risk for HIV infection [1]. Randomized controlled trials have demonstrated that daily oral PrEP dramatically reduces the risk of HIV infection when it is taken as directed. Concerns regarding widespread emergence of antiretroviral resistance attributable to PrEP and behavioral disinhibition have to date not been observed in clinical trials and open-label demonstration projects. PrEP has great potential as part of an HIV risk reduction strategy and barriers to wider implementation including community education, prescriber availability, and elimination of financial barriers should be aggressively pursued. Adherence is critical to PrEP efficacy and has varied across study populations; developing and refining ways of measuring and supporting adherence is essential to the success of PrEP. Evaluation of long-acting medications and alternative formulations for PrEP is underway and may lead to the wider implementation and impact of PrEP.

Keywords: HIV Prevention; Pre-exposure prophylaxis; antiretrovirals.

PubMed Disclaimer

References

    1. Centers for Disease Control and Prevention . Pre-Exposure Prophylaxis for the Prevention of HIV in the United States - 2014 Clinical Practice Guideline. 2014.
    1. Baeten JM, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. [The Partners-PrEP study was one of the first large studies of heterosexual discordant couples indicating significant risk reduction with daily oral TDF or TDF/FTC PrEP. Substudies and open-label continuation phase from this study continue to contribute information regarding durability of effect and factors related to adherence.] - PMC - PubMed
    1. Choopanya K, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90. [This is the largest controlled trial demonstrating the efficacy and feasibility of of oral PrEP for IDU in Thailand.] - PubMed
    1. Grant RM, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99. [The iPrEX study was the first large placebo controlled trial to demonstrate risk reductions with PrEP and was conducted in MSM and TGW. Substudies have contributed substantially to information regarding correlates between adherence and protection in this population.] - PMC - PubMed
    1. Thigpen MC, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34. [The CDC TDF-2 study contributed to available data regarding efficacy of PrEP for prevention of heterosexual HIV transmission.] - PubMed

LinkOut - more resources